ACP-106

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameACP-106
Drug Alias Name5-HT2A inverse agonists (ACADIA)ACP-106
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor inverse agonists
TargetsSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsSleep Wake DisordersCentral Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAcadia Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAcadia Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSleep Wake DisordersCentral Nervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A